Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
84257 trials found · Page 13 of 4213
-
Major trial aims to boost remission rates for seniors with aggressive blood cancer
Disease control Not yet recruitingThis is a multicenter, open-label, randomized, controlled phase III clinical trial designed to evaluate the efficacy and safety of the combination of Venetoclax, Azacitidine, and Homoharringtonine (VAH) compared to Venetoclax and Azacitidine (VA) alone in newly diagnosed elderly …
Phase: PHASE3 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
New hope for tough pancreatic cancer: major trial tests drug combo
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
New hope for tough lung cancer: experimental drugs challenge standard chemotherapy
Disease control Not yet recruitingThis is a randomized, open-label, multi-center, global phase II/III clinical study to evaluate the efficacy and safety of HLX43 monotherapy or HLX43 in combination with HLX07 vs. docetaxel in the treatment of advanced squamous NSCLC after failure of first-line treatment.
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
New drug trial aims to slow devastating ALS progression
Disease control Not yet recruitingFIH, Phase 1/2, multi-centre, randomised, double-blind, placebo controlled study with an optional open-label dosing extension to assess the safety, tolerability, efficacy, and Pharmacodynamics (PD) of single or multiple (up to 48 weeks QD) subcutaneous (SC) doses of PLL001 compar…
Phase: PHASE1, PHASE2 • Sponsor: PLL TX AUSTRALIA PTY LTD • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New drug aims to keep aggressive blood cancer at bay
Disease control Not yet recruitingThe purpose of this study is to evaluate the therapeutic benefit and safety of subcutaneous (SC) Surovatamig monotherapy as consolidation therapy in patients with Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) with unmutated IGHV (uIGHV).
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 06, 2026 14:14 UTC
-
New hope for ICU patients in Life-Threatening shock
Disease control Recruiting nowAcute circulatory failure (shock) is defined as insufficient oxygen transport to meet the oxygen requirements of organs and tissues. Vasoplegic shock is the most frequent cause of shock, defined by vasoplegia and a drop in arterial pressure with preserved cardiac output. The main…
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Apr 20, 2026 16:13 UTC
-
Brain cell implants tested in groundbreaking Huntington's trial
Disease control Recruiting nowThe purpose of this research study is to determine whether an implantation of hNSC-01 is a safe and tolerable study intervention for Huntington's disease. This study is the first time that hNSC-01 is being tested in people.
Phase: PHASE1, PHASE2 • Sponsor: Leslie Thompson • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
New treatment could help throat cancer patients avoid Voice-Box removal surgery
Disease control Recruiting nowThis trial will study the safety and tolerability and disease survival rates in adult patients with recurrent/metastatic (R/M) HNSCC when treated with carboplatin or cisplatin, paclitaxel, and toripalimab.
Phase: PHASE2 • Sponsor: Matthew Spector • Aim: Disease control
Last updated Apr 16, 2026 12:47 UTC
-
New drug trial aims to slow scarring of the lungs
Disease control Not yet recruitingThis study is open to adults with PPF . The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
Phase: PHASE3 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
One-Shot gene therapy aims to free patients from lifelong transfusions
Disease control Not yet recruitingThe goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating patients with β-Thalassemia Major
Phase: PHASE2 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC
-
New drug trial aims to halt deadly lung scarring
Disease control Not yet recruitingThis study aims to evaluate the efficacy and safety of HSK44459 tablets in patients with idiopathic pulmonary fibrosis (IPF).
Phase: PHASE3 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Apr 13, 2026 20:21 UTC
-
New 'Living Drug' trial offers hope for Tough-to-Treat blood cancer
Disease control Not yet recruitingThis study is an open-label, single-arm, prospective, exploratory clinical trial involving patients with relapsed/refractory large B-cell lymphoma, aiming to preliminarily assess the safety and efficacy of CAR-T cell infusion.
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 13, 2026 20:18 UTC
-
New vaccine aims to stop malaria before it makes you sick
⭐️ VACCINE ⭐️ Not yet recruitingThis is a phase 2 clinical trial of a Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) vaccine (Sanaria® PfSPZ-LARC2 Vaccine) that will assess field efficacy in Africa. The PfSPZ comprising PfSPZ-LARC2 Vaccine contain a double d…
Phase: PHASE2 • Sponsor: Sanaria Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 06, 2026 14:17 UTC
-
New drug trial aims to stop Alzheimer's before it starts in High-Risk group
Prevention Not yet recruitingPrimary Objectives: To demonstrate that HT-4253 improves the amyloid risk profile by transitioning biomarker-positive APOE4 carriers from a positive, high risk APS2 score to a negative, low risk APS2 score. Secondary Objectives: * To assess the effects of HT-4253 on tau relate…
Phase: PHASE2 • Sponsor: Halia Therapeutics, Inc. • Aim: Prevention
Last updated Apr 14, 2026 13:09 UTC
-
New hope for stomach cancer patients after first treatment fails
Disease control Not yet recruitingThis is a phase III, Multicenter, Randomized study, evaluating the efficacy and Safety of LM-108(an Anti-CCR8 mAb) in combination With Toripalimab Versus Paclitaxel Injection in subjects with CCR8-Positive locally advanced or metastatic Gastric Cancer and Gastroesophageal Junctio…
Phase: PHASE3 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
New spinal injection aims to boost muscle function in SMA
Disease control Not yet recruitingIn this study, researchers will learn more about the effects and safety of BIIB115, also known as salanersen. Specifically, researchers will learn more about how salanersen works in individuals with SMA who are between the ages of 15 and 60 years old. In most people living with …
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Apr 17, 2026 16:10 UTC
-
New drug combo aims to keep ovarian cancer at bay longer
Disease control Recruiting nowThis Phase 3 study will be conducted in different countries around the world with up to about 528 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with available standard of care therapy that is already approved a…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
Double attack on deadly cancer: new trial aims to control aggressive tumors
Disease control Not yet recruitingBackground: Small-cell lung cancer (SCLC) is the most deadly form of lung cancer. It kills at least 250,000 worldwide each year. Extra-pulmonary neuroendocrine cancer (EP-NEC) is a similar type of cancer that develops anywhere other than the lungs. EP-NEC is also very aggressive…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New Two-Target CAR-T therapy tested for tough blood cancers
Disease control Not yet recruitingThis is a single arm study to evaluate the safety and efficacy of CAR19BCMA CAR-T cells in the treatment of relapsed/refractory CD19/BCMA positive plasma cell neoplasms and lymphomas/leukemias with plasmacytic differentiation.
Phase: EARLY_PHASE1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
Gene injection aims to restore hearing in deaf children
Disease control Recruiting nowThis study is a multicenter, single-arm, open-label Phase I/II clinical trial, which is designed to evaluate the safety, tolerability and efficacy of EHT102 injection in treating congenital hearing loss secondary to biallelic mutations of OTOF (DFNB9).Up to 30 pediatric participa…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Euhearing Therapeutics Co., Ltd • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC